Randomized Controlled Trial
. 2017 Nov;66(11):1975-1982. doi: 10.1136/gutjnl-2016-311819. Epub 2016 Aug 9. A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening M van der Vlugt 2 , A J van Vuuren 1 , A K Stroobants 3 , M W Mundt 4 , W J Spijker 5 , E J C Bongers 6 , E J Kuipers 1 , I Lansdorp-Vogelaar 7 , P M Bossuyt 8 , E Dekker 2 , M C W Spaander 1Affiliations
AffiliationsItem in Clipboard
Randomized Controlled Trial
A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screeningE J Grobbee et al. Gut. 2017 Nov.
. 2017 Nov;66(11):1975-1982. doi: 10.1136/gutjnl-2016-311819. Epub 2016 Aug 9. Authors E J Grobbee 1 , M van der Vlugt 2 , A J van Vuuren 1 , A K Stroobants 3 , M W Mundt 4 , W J Spijker 5 , E J C Bongers 6 , E J Kuipers 1 , I Lansdorp-Vogelaar 7 , P M Bossuyt 8 , E Dekker 2 , M C W Spaander 1 AffiliationsItem in Clipboard
AbstractObjective: Colorectal cancer screening programmes are implemented worldwide; many are based on faecal immunochemical testing (FIT). The aim of this study was to evaluate two frequently used FITs on participation, usability, positivity rate and diagnostic yield in population-based FIT screening.
Design: Comparison of two FITs was performed in a fourth round population-based FIT-screening cohort. Randomly selected individuals aged 50-74 were invited for FIT screening and were randomly allocated to receive an OC -Sensor (Eiken, Japan) or faecal occult blood (FOB)-Gold (Sentinel, Italy) test (March-December 2014). A cut-off of 10 µg haemoglobin (Hb)/g faeces (ie, 50 ng Hb/mL buffer for OC-Sensor and 59 ng Hb for FOB-Gold) was used for both FITs.
Results: In total, 19 291 eligible invitees were included (median age 61, IQR 57-67; 48% males): 9669 invitees received OC-Sensor and 9622 FOB-Gold; both tests were returned by 63% of invitees (p=0.96). Tests were non-analysable in 0.7% of participants using OC-Sensor vs 2.0% using FOB-Gold (p<0.001). Positivity rate was 7.9% for OC-Sensor, and 6.5% for FOB-Gold (p=0.002). There was no significant difference in diagnostic yield of advanced neoplasia (1.4% for OC-Sensor vs 1.2% for FOB-Gold; p=0.15) or positive predictive value (PPV; 31% vs 32%; p=0.80). When comparing both tests at the same positivity rate instead of cut-off, they yielded similar PPV and detection rates.
Conclusions: The OC-Sensor and FOB-Gold were equally acceptable to a screening population. However, FOB-Gold was prone to more non-analysable tests. Comparison between FIT brands is usually done at the same Hb stool concentration. Our findings imply that for a fair comparison on diagnostic yield between FIT's positivity rate rather than Hb concentration should be used.
Trial registration number: NTR5385; Results.
Keywords: COLORECTAL CANCER SCREENING; COLORECTAL CARCINOMA.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Similar articlesSchreuders EH, Grobbee EJ, Nieuwenburg SAV, Kapidzic A, van Roon AHC, van Vuuren AJ, Lansdorp-Vogelaar I, Spijker WWJ, Izelaar K, Bruno MJ, Kuipers EJ, Spaander MCW. Schreuders EH, et al. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):622-631. doi: 10.1016/S2468-1253(19)30176-1. Epub 2019 Jun 10. Lancet Gastroenterol Hepatol. 2019. PMID: 31196734
Wieten E, de Klerk CM, van der Steen A, Ramakers CR, Kuipers EJ, Hansen BE, Lansdorp-Vogelaar I, Bossuyt PM, Dekker E, Spaander MCW. Wieten E, et al. Gastroenterology. 2018 Nov;155(5):1392-1399.e5. doi: 10.1053/j.gastro.2018.07.021. Epub 2018 Jul 25. Gastroenterology. 2018. PMID: 30055170
de Klerk CM, Wieten E, Lansdorp-Vogelaar I, Bossuyt PM, Spaander MC, Dekker E. de Klerk CM, et al. Lancet Gastroenterol Hepatol. 2019 Feb;4(2):111-118. doi: 10.1016/S2468-1253(18)30319-4. Epub 2018 Nov 27. Lancet Gastroenterol Hepatol. 2019. PMID: 30497962
Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, Al M, Armstrong N, Kleijnen J. Westwood M, et al. Health Technol Assess. 2017 May;21(33):1-234. doi: 10.3310/hta21330. Health Technol Assess. 2017. PMID: 28643629 Free PMC article. Review.
Grobbee EJ, Wisse PHA, Schreuders EH, van Roon A, van Dam L, Zauber AG, Lansdorp-Vogelaar I, Bramer W, Berhane S, Deeks JJ, Steyerberg EW, van Leerdam ME, Spaander MC, Kuipers EJ. Grobbee EJ, et al. Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD009276. doi: 10.1002/14651858.CD009276.pub2. Cochrane Database Syst Rev. 2022. PMID: 35665911 Free PMC article. Review.
Gingold-Belfer R, Leibovitzh H, Boltin D, Issa N, Tsadok Perets T, Dickman R, Niv Y. Gingold-Belfer R, et al. United European Gastroenterol J. 2019 Apr;7(3):424-448. doi: 10.1177/2050640619828185. Epub 2019 Feb 6. United European Gastroenterol J. 2019. PMID: 31019712 Free PMC article.
de Klerk CM, Vendrig LM, Bossuyt PM, Dekker E. de Klerk CM, et al. Am J Gastroenterol. 2018 Dec;113(12):1778-1787. doi: 10.1038/s41395-018-0212-7. Epub 2018 Aug 29. Am J Gastroenterol. 2018. PMID: 30158713 Free PMC article.
Brenner H, Werner S. Brenner H, et al. Clin Transl Gastroenterol. 2017 Aug 3;8(8):e111. doi: 10.1038/ctg.2017.37. Clin Transl Gastroenterol. 2017. PMID: 28771240 Free PMC article.
van der Vlugt M, Grobbee EJ, Bossuyt PM, Bongers E, Spijker W, Kuipers EJ, Lansdorp-Vogelaar I, Essink-Bot ML, Spaander MC, Dekker E. van der Vlugt M, et al. Br J Cancer. 2017 Jan 3;116(1):44-49. doi: 10.1038/bjc.2016.399. Epub 2016 Dec 6. Br J Cancer. 2017. PMID: 27923037 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3